Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02550145 · ClinicalTrials.gov registry record · Phase 1
Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric Surgery
A Phase 1 study, sponsored by Tracey McLaughlin.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT02550145 is a Phase 1 study that was terminated before completion, run by Tracey McLaughlin. The registered enrollment target is 10 participants.
The verdict
NCT02550145, a Phase 1 study, was terminated before completion, sponsored by Tracey McLaughlin.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the role of GLP-1 in causing extreme postprandial glucose reductions after bariatric surgery in a subset of patients who have severe symptomatic hypoglycemia.
Interventions
- OTHER Placebo
- DRUG Exendin (9-39)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02550145
The ClinicalTrials.gov registry entry for NCT02550145 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tracey McLaughlin, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02550145 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02550145 about?
NCT02550145 is a clinical study titled "Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric Surgery". The purpose of this study is to evaluate the role of GLP-1 in causing extreme postprandial glucose reductions after bariatric surgery in a subset of patients who have severe symptomatic hypoglycemia.
What is the current status of trial NCT02550145?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2014-02.
What interventions are being tested in trial NCT02550145?
The interventions under investigation include: Placebo (OTHER), Exendin (9-39) (DRUG).
Who is sponsoring clinical trial NCT02550145?
This trial is sponsored by Tracey McLaughlin, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.